IDO activity, expressed as kyn/trp ratio, is associated with response to immunotherapy; in particular, higher kyn/trp ratio could predict resistance to anti-PD-1 treatment. These preliminary results suggest the possibility of using anti-PD-1 plus IDO inhibitor in those patients with high level ...
PD1、PD-L1、淋巴细胞浸润、TMB等等这些都是已知的标志物,此外T细胞克隆扩增也能预示着ICB的治疗响应。这篇文章也是以此为出发点展开的课题。 实验设计 取anti-PD1治疗前后的配对样本,同时进行scRNA-seq和scTCR-seq。根据T细胞的克隆型将病人分成了克隆扩增(E)和没有克隆扩增(NE)两组。 结果 文章的很多结果都是...
In syngeneic tumor models, anti-PD-1 treatment increases the number of tumor-infiltrating TFR cells. Both TFR cell deficiency and the depletion of TFR cells with anti-CTLA-4 before anti-PD-1 treatment improve tumor control in mice. Notably, in a cohort of 271 patients with melanoma, ...
着眼现在,陈教授认为,anti-PD治疗在癌症领域最重要的关注点为:了解耐药机制(undersatnd the resistance)、更多可靠的生物标记物(more reliable biomarker)、改进现行治疗(Beyond current treatment regimes)。 1 Undersatnd the resistance 陈教授将anti-PD...
总的来说，研究对转移性肾透明细胞癌在anti-PD-1治疗前和后的基因组和肿瘤免疫微环境的特征进行了详细的描绘，揭示出患者对anti-PD-1有响应的决定性因素，或对ccRCC病人的精准医疗具有参考价值。原文链接：https://doi.org/10.1016/j.ccell.2021.10.001 参考文献 1. Fridman, W.H., Zitvogel, L., Saute...
anti-PD-1, or anti-GDF-15, or both, or isotype control antibody. In both settings, combination treatment induced tumor regressions (Fig.4a, b). Taking either the value on day 29 or the last bioluminescent measurement as endpoint, only the combination treatment achieved a statistically ...
ANTI-PD-1抗体及其用途.pdf,本公开内容涉及一种结合至程序性细胞死亡‑1(PD‑1)蛋白质的蛋白质结合剂、抗体、其抗原结合片段。本公开内容提供额外对本公开内容的蛋白质结合剂、抗体、其抗原结合片段进行加密的多核苷酸序列、包含其的载体、宿主细胞。另外,本公开内容提
CPI治疗中,高T/低髓系细胞浸润和B细胞丰度高分别在anti-PD-L1和anti-PD-1响应患者中富集。然而,这些特征作为预测性生物标记物的交叉验证产生了不一致的结果【2】,这可能是由于免疫肿瘤内异质性(ITH),尤其是因为先前的研究依赖于对...
背景[1-3] ANTI-PD-L1抗体是一类可以特异性结合PD-L1的多克隆抗体,主要用于检测PD-L1的Western Blot、IHC-P、IF、ELISA、Co-IP等多种免疫学实验。 检测原理:双抗体夹心法测定标本中PD-L1水平。用纯化的PD-L1抗体包被微孔板,制成固相抗体,往包被单抗的微孔中依次加入PD-L1,再与HRP标记的PD-L1抗体结合,形成...
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancerhttps://doi.org/10.1038/s41591-021-01323-8 前言(CNS复现)CLAM--Chapter_00_YuanSh1106的博客-CSDN博…